Galantamine interactions

Pyridostigmine bromide extended-release tablets are contraindicated in patients with: Mechanical intestinal or urinary obstruction Known hypersensitivity to pyridostigmine or other anticholinesterase agents Mechanical intestinal or urinary obstruction. (Pyridostigmine label, Contraindications)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamine label, Warnings and precautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamine label, Warnings and precautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamine label, Warnings and precautions)

Gastrointestinal Conditions Through their primary action, cholinomimetics may be expected to increase gastric acid secretion due to increased cholinergic activity. (Galantamine label, Warnings and precautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamine label, Warnings and precautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamine label, Warnings and precautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamine label, Warnings and precautions)

Gastrointestinal Conditions Through their primary action, cholinomimetics may be expected to increase gastric acid secretion due to increased cholinergic activity. (Galantamine label, Warnings and precautions)

Cholinesterase inhibitors: Concomitant administration may increase the risk of cocaine toxicity. (Cocaine label, Drug interactions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamine label, Warnings and precautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamine label, Warnings and precautions)

Dicyclomine hydrochloride should be given to patients with myasthenia gravis only to reduce adverse muscarinic effects of an anticholinesterase (5.4) (Dicyclomine label, Warnings and precautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamine label, Warnings and precautions)

Anticholinesterases: BREVIBLOC prolonged the duration of succinylcholine-induced neuromuscular blockade and moderately prolonged clinical duration and recovery index of mivacurium. (Esmolol label, Drug interactions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamine label, Warnings and precautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamine label, Warnings and precautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamine label, Warnings and precautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamine label, Warnings and precautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamine label, Warnings and precautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamine label, Warnings and precautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamine label, Warnings and precautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamine label, Warnings and precautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamine label, Warnings and precautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamine label, Warnings and precautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamine label, Warnings and precautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamine label, Warnings and precautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamine label, Warnings and precautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamine label, Warnings and precautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamine label, Warnings and precautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamine label, Warnings and precautions)

Use with caution due to aggravation of symptoms: Pre-existing dementia in patients treated with cholinesterase inhibitors ( 5.2 ), Parkinson’s disease ( 5.2 ), Myasthenia gravis ( 5.3 ), and Decreased gastrointestinal motility in patients with autonomic neuropathy ( 5.4 ). (Oxybutynin label, Warnings and precautions)

In case of simultaneous administration of other cholinesterase inhibitors (e.g. medicines for the treatment of dementia), caution should be exercised because of the potentiating effect. (Physostigmine label, Drug interactions)

Gastrointestinal Conditions Through their primary action, cholinomimetics may be expected to increase gastric acid secretion due to increased cholinergic activity. (Galantamine label, Warnings and precautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamine label, Warnings and precautions)

Myasthenia Gravis Patients with myasthenia gravis may show worsening of symptoms from PA due to its procaine-like effect on diminishing acetylcholine release at skeletal muscle motor nerve endings, so that PA administration may be hazardous without optimal adjustment of anticholinesterase medications and other precautions. (Procainamide label, Warnings)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamine label, Warnings and precautions)

Gastrointestinal Conditions Through their primary action, cholinomimetics may be expected to increase gastric acid secretion due to increased cholinergic activity. (Galantamine label, Warnings and precautions)

When Phase II block is suspected in cases of prolonged neuromuscular blockade, positive diagnosis should be made by peripheral nerve stimulation, prior to administration of any anticholinesterase drug. (Succinylcholine label, Warnings and precautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamine label, Warnings and precautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamine label, Warnings and precautions)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamine label, Warnings and precautions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Anesthesia Galantamine, as a cholinesterase inhibitor, is likely to exaggerate the neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia. (Galantamine label, Warnings and precautions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Anesthesia Galantamine, as a cholinesterase inhibitor, is likely to exaggerate the neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia. (Galantamine label, Warnings and precautions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Anesthesia Galantamine, as a cholinesterase inhibitor, is likely to exaggerate the neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia. (Galantamine label, Warnings and precautions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Anticholinesterases Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (Dexamethasone label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Cholinesterase Inhibitors Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis. (Dipyridamole label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Synergistic effect expected when given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents, or cholinergic agonists ( 7.2 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Anesthesia Galantamine, as a cholinesterase inhibitor, is likely to exaggerate the neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia. (Galantamine label, Warnings and precautions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Synergistic effect expected when given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents, or cholinergic agonists ( 7.2 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Anticholinesterases : Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (Methylprednisolone label, Drug interactions)

Synergistic effect expected when given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents, or cholinergic agonists ( 7.2 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Anesthesia Galantamine, as a cholinesterase inhibitor, is likely to exaggerate the neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia. (Galantamine label, Warnings and precautions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Anticholinesterase agents: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (Prednisolone label, Drug interactions)

Anticholinesterase Agents Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (Prednisone label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Synergistic effect expected when given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents, or cholinergic agonists ( 7.2 ) (Galantamine label, Drug interactions)

Anesthesia Galantamine, as a cholinesterase inhibitor, is likely to exaggerate the neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia. (Galantamine label, Warnings and precautions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Anticholinesterases: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (Triamcinolone label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (Galantamine label, Drug interactions)

Anesthesia Galantamine, as a cholinesterase inhibitor, is likely to exaggerate the neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia. (Galantamine label, Warnings and precautions)

In drug interaction studies, oral RISPERDAL did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6. (Risperidone label, Drug interactions)